Tarsons Products Ltd

Tarsons Products Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. This closure will be effective from July 1, 2026, and will continue until 48 hours after the declaration of the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. The company has informed all designated persons about this restriction, prohibiting them from trading in the company's securities during this period. Details regarding the board meeting to approve these financial results will be communicated later. The information is also available on the company's website.

Tarsons Products Ltd has responded to a clarification sought by the stock exchange regarding a significant movement in its share price. The company stated that it has been compliant with SEBI regulations, regularly updating investors on material information. Tarsons confirmed there is no pending or undisclosed material information that could impact its operations or performance. The company attributed any share volume movement to market-driven factors and reiterated its commitment to adhering to all applicable laws and listing regulations.

Tarsons Products Ltd has responded to a clarification sought by the stock exchange regarding a recent spurt in trading volume. The company stated that it complies with SEBI regulations and has disclosed all material information that could impact its operations or stock price. Tarsons Products confirmed there is no pending or undisclosed material information. The company attributed the volume movement to market-driven factors and reiterated its commitment to regulatory compliance.

Tarsons Products Ltd has announced the resignation of Mr. Subhra Shankar Bose, Head of Human Resources, a key Senior Management Personnel. The resignation is effective from June 15, 2026, with Mr. Bose serving a three-month notice period as per his employment contract. He cited personal reasons and a desire to pursue new opportunities for growth as the basis for his decision. The company has acknowledged his resignation and will host this intimation on its website. This marks a change in senior management within the company's HR function.

Tarsons Products Ltd has completed the second tranche of its equity investment in its wholly-owned Singaporean subsidiary, Tarsons Life Science Pte. Ltd. This tranche amounts to EUR 552,000, with the company subscribing to 184 equity shares. This investment is part of a larger approved equity infusion of EUR 3,000,000. The funds will be utilized by the subsidiary for loan repayment, interest payments, and general corporate purposes. This follows the first tranche of EUR 300,000 completed earlier. The company will continue to provide updates on subsequent tranches.

Tarsons Products Ltd has re-appointed M/s. Grant Thornton Bharat LLP as the Internal Auditors for the financial year 2026-27, following the recommendation of the Audit Committee. This decision was made during the Board of Directors meeting held on May 22, 2026. The board also approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, with an unmodified opinion from the Statutory Auditors, M/s. Price Waterhouse Chartered Accountants LLP.

Tarsons Products Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, in a meeting held on May 22, 2026. The board also approved the re-appointment of M/s. Grant Thornton Bharat LLP as the Internal Auditors for the Financial Year 2026-27. The Statutory Auditors, M/s. Price Waterhouse Chartered Accountants LLP, issued an unmodified opinion on the audited financial results.

Tarsons Products Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, in a meeting held on May 22, 2026. The board also approved the re-appointment of M/s. Grant Thornton Bharat LLP as the Internal Auditors for the financial year 2026-27, based on the recommendation of the Audit Committee. The Statutory Auditors, M/s. Price Waterhouse Chartered Accountants LLP, issued an unmodified opinion on the audited financial results.

Tarsons Products Ltd has scheduled a Board of Directors meeting on May 22, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The meeting will also include a review of the Audit Report of the Statutory Auditors. The trading window for dealing in the company's securities will remain closed until 48 hours post the declaration of the financial results.

Tarsons Products Ltd has announced the appointment of Mr. Mani Kalyan Dusi as Head – Revenue (India & APAC), designated as a Senior Management Personnel (SMP). The Board of Directors approved this appointment based on the Nomination & Remuneration Committee's recommendation. Mr. Dusi is expected to join the company on or before May 20, 2026. He brings over 18 years of extensive experience in the life sciences, pharmaceuticals, and academic sectors across the APAC region. His expertise includes commercial leadership, strategic marketing, go-to-market strategies, and P&L management, with a proven track record of driving business growth. He previously held key leadership roles at Merck Life Science and Thermo-Fisher Scientific.